Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Evolus Inc
(NQ:
EOLS
)
11.64
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
11.64
Bid (Size)
10.02 (1)
Ask (Size)
15.22 (2)
Prev. Close
11.64
Today's Range
11.64 - 11.64
52wk Range
7.070 - 15.43
Shares Outstanding
54,576,156
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From
Evolus
Via
Business Wire
Performance
YTD
+16.52%
+16.52%
1 Month
-16.86%
-16.86%
3 Month
-6.73%
-6.73%
6 Month
+43.17%
+43.17%
1 Year
+42.65%
+42.65%
More News
Read More
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Evolus
Via
Business Wire
Recap: Evolus Q4 Earnings
March 07, 2024
Via
Benzinga
Earnings Outlook For Evolus
March 06, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 21, 2024
Via
Benzinga
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Evolus
Via
Business Wire
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
February 14, 2024
Via
Investor's Business Daily
Evolus Inc. (NASDAQ: EOLS) Leading the Way in Wednesday Trading Based on Percentage Gain
January 17, 2024
Via
Investor Brand Network
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
March 07, 2024
Via
InvestorPlace
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From
Evolus
Via
Business Wire
Evolus Announces Results from European Head-to-Head Filler Trial
March 01, 2024
From
Evolus
Via
Business Wire
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
February 27, 2024
From
Evolus
Via
Business Wire
Earnings Scheduled For March 7, 2024
March 07, 2024
Via
Benzinga
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
February 22, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2024
From
Evolus
Via
Business Wire
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
February 01, 2024
Via
Investor's Business Daily
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 29, 2024
Via
Benzinga
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
January 29, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker
January 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 17, 2024
Via
Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
January 16, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From
Evolus
Via
Business Wire
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
January 11, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.